Search

Roche Holding AG

Atvērts

SektorsVeselības aprūpe

294.8 -2.06

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

291

Max

302.2

Galvenie mērījumi

By Trading Economics

Ienākumi

6.3B

Pārdošana

31B

P/E

Sektora vidējais

29.748

63.778

Dividenžu ienesīgums

3.1

Peļņas marža

20.347

Darbinieki

103,249

EBITDA

11B

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.10%

2.39%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

233B

Iepriekšējā atvēršanas cena

296.86

Iepriekšējā slēgšanas cena

294.8

Ziņu noskaņojums

By Acuity

48%

52%

176 / 386 Rangs Healthcare

Roche Holding AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. marts 09:23 UTC

Galvenie tirgus virzītāji

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

2025. g. 30. janv. 09:36 UTC

Peļņas

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

2025. g. 30. janv. 06:32 UTC

Peļņas

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

2024. g. 26. nov. 15:27 UTC

Iegādes, apvienošanās, pārņemšana

Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion

2025. g. 31. marts 09:31 UTC

Karstas akcijas

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

2025. g. 13. marts 07:46 UTC

Tirgus saruna

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

2025. g. 12. marts 16:34 UTC

Top Ziņas

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

2025. g. 12. marts 08:51 UTC

Tirgus saruna

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

2025. g. 12. marts 08:18 UTC

Tirgus saruna

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

2025. g. 13. febr. 11:43 UTC

Tirgus saruna

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

2025. g. 30. janv. 07:56 UTC

Tirgus saruna
Peļņas

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

2025. g. 30. janv. 06:04 UTC

Peļņas

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

2025. g. 30. janv. 06:04 UTC

Peļņas

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

2025. g. 30. janv. 06:04 UTC

Peļņas

Roche Issues 2025 View

2025. g. 30. janv. 06:03 UTC

Peļņas

Roche Raises Dividend to CHF9.70 Vs CHF9.60

2025. g. 30. janv. 06:03 UTC

Peļņas

Roche 2024 Core Operating Profit CHF20.82B

2025. g. 30. janv. 06:03 UTC

Peļņas

Roche 2024 Net Pft CHF9.19B

2025. g. 30. janv. 06:02 UTC

Peļņas

Analysts Saw 2024 Core EPS at CHF18.59

2025. g. 30. janv. 06:02 UTC

Peļņas

Roche 2024 Core EPS CHF18.80

2025. g. 30. janv. 06:02 UTC

Peļņas

Roche 2024 Sales EUR60.50B

2025. g. 30. janv. 06:02 UTC

Peļņas

Analysts Saw Roche 2024 Revenue at CHF60.41B

2025. g. 30. janv. 06:01 UTC

Peļņas

Roche 2024 Sales CHFB

2025. g. 28. janv. 10:30 UTC

Top Ziņas

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

2025. g. 28. janv. 07:24 UTC

Tirgus saruna

Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk

2025. g. 15. janv. 10:22 UTC

Tirgus saruna

Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk

2025. g. 8. janv. 06:15 UTC

Iegādes, apvienošanās, pārņemšana

Roche: 66.11% of Poseida's Shares Were Validly Tendered in Offer

2025. g. 8. janv. 06:12 UTC

Iegādes, apvienošanās, pārņemšana

Roche Intends to Complete Acquisition of Poseida Therapeutics Later Wednesday

2024. g. 16. dec. 22:03 UTC

Top Ziņas

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

2024. g. 13. dec. 16:36 UTC

Tirgus saruna

Swiss Equities an Overweight Pick Next Year -- Market Talk

2024. g. 26. nov. 16:10 UTC

Iegādes, apvienošanās, pārņemšana

Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com

Roche Holding AG Prognoze

Noskaņojums

By Acuity

176 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.